Showing 2551-2560 of 6036 results for "".
- Staar Surgical Celebrates Three Million Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1] “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction
- Neurolens Restructures Leadership Teamhttps://modernod.com/news/neurolens-restructures-leadership-team/2482165/Neurolens announced a strategic leadership restructure, which includes Davis Corley, co-founder, returning as CEO. Other leadership hires: Gregory Boisse, SVP of Operations Nathan Schomas, SVP of Digital Innovation
- Survey: Communications Adjustments Could Supercharge Contact Lens Adoptionhttps://modernod.com/news/survey-communications-adjustments-could-supercharge-contact-lens-adoption/2482164/Simple adjustments to how eye care practices communicate with patients may attract a significantly higher number of contact lens wearers, according to new data from the Contact Lens Institute (CLI). The industry association is previewing its latest
- Richard Lindstrom, MD, to Lead Eye Care Biopharmaceutical Company Surface Ophthalmicshttps://modernod.com/news/richard-lindstrom-md-to-lead-new-eye-care-biopharmaceutical-company-surface-ophthalmics/2482161/Surface Ophthalmics announced the appointment of Richard Lindstrom, MD, as Founder and Chairman. Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, PA. Dr. Lindstrom will lead in partnership with Surface’s Board of Directors, including
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com
- The Vision Council’s Membership Base to Include Healthcare, Technology, and Contact Lens Companieshttps://modernod.com/news/the-vision-councils-membership-base-to-include-healthcare-technology-and-contact-lens-companies/2482157/The Vision Council has expanded its membership structure to include healthcare, technology, and contact lens companies, according to a company news release. "With guidance from our Board of Directors to ensure that The Vision Council is both reflective of our evolving industry
- Research: AI Has Perfect Detection Rate for Severe Cases of Retinopathy of Prematurity (ROP)https://modernod.com/news/research-ai-has-perfect-detection-rate-for-severe-cases-of-retinopathy-of-prematurity-rop/2482153/New research from Oregon Health & Science University (OHSU) and collaborators reveal that artificial intelligence technology can accurately and independently detect 100% of severe cases of retinopathy of prematurity (ROP). The research was
- Neurolenses Demonstrate Headache Relief in New Studyhttps://modernod.com/news/neurolenses-demonstrate-headache-relief-in-new-study/2482145/Neurolens announced results of a company-sponsored study evaluating the impact of Neurolens prescription lenses on individuals with headaches. The six-item Headache Impact Test (H
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Nicox Names New CEO; Restructures Debt to Focus on NCX 470 Pivotal Trialhttps://modernod.com/news/nicox-names-new-ceo-restructures-debt-to-focus-on-ncx-470-pivotal-trial/2482137/Nicox announced this week that its Board of Directors has promoted Gavin Spencer to Chief Executive Officer. He previously served as Executive Vice-President, Chief Business Officer & Head of Corporate Development. Mr. Gavin will be replacing Andreas Segerros, whose mandat